ClinicalTrials.gg
Status unknownNCT02296281Updated Nov 20, 2014

Safety and Efficacy Study of Pirfenidone to Treat Grade 2 or Above Radiation-induced Lung Injury

A Phase 2 interventional study of Pirfenidone in Radiation Pneumonitis, sponsored by Beijing Continent Pharmaceutical Co, Ltd.. Status unknown. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-11-20.

Sponsored by Beijing Continent Pharmaceutical Co, Ltd. (part of GNI Group Ltd.) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2014), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
48
Allocation
Not applicable
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to assess the safety and efficacy of pirfenidone capsules to treat grade 2 or above radiation-induced lung injury patients.

02

Conditions studied

  • Radiation Pneumonitis

Browse trials for

03

In context

Radiation Pneumonitis

39 studies on the registry are indexed under Radiation Pneumonitis; 16 are open to participants now.

This study's planned enrollment of 48 is below the median of 61 across 24 interventional studies indexed under Radiation Pneumonitis.

Browse Radiation Pneumonitis studies →

Lead sponsor

Beijing Continent Pharmaceutical Co, Ltd. is the lead sponsor of 26 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18-70 years old (include 18 and 70 years), male or female
  2. The pathological diagnosis of lung cancer, with non-small cell lung cancer (NSCLC) staging IIIA or IIIB, and small cell lung cancer (SCLC) in council deadline
  3. General condition assessment, score of 0-1
  4. Enough heart, liver and kidney function, such as , ALT, LDH≤2 times such as plasma total , creatinine ≤1.5 times ULN; hematopoietic function enough, such as neutrophils ≥4.0 x109 / L, ≥100 x109 / L
  5. The expected survival at 6 months or more
  6. Subject is able to eat solid food
  7. The initial radical thoracic radiotherapy treatment
  8. The clinical diagnosis of radiation-induced lung injury in Grade 2 or above
  9. The duration of radiation-induced lung injury in less than 1 month
  10. Signed

Exclusion criteria

Exclusion Criteria:

  1. Radiation-induced lung injury has entered the chronic phase
  2. A history of chronic bronchitis, emphysema, or a history of cor pulmonale
  3. Lung resection surgery
  4. Cancer progression
  5. Pulmonary infection
  6. Associated with other serious diseases: such as occurred within 6 months of myocardial infarction, uncontrolled diabetes etc.
  7. With active peptic ulcer
  8. Pregnant women and patients with mental disease
  9. Those who participate in clinical trials of other drugs within 3 months
  10. Investigator judge does not apply to participate in the trial
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
48 participants (estimated)

Study arms

  • Experimental
    treatment group

    Drug: Pirfenidone

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in radiation-induced lung injury classification

    Time frame: 36 Weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2015 and a primary completion of Jun 2016. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2014
First posted
Nov 20, 2014
Start
Jan 2015
Primary completionEst.
Jun 2016
Last update
Nov 20, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02296281
Collaborators
Shanghai Genomics, Inc., GNI-EPS Pharmaceuticals, Inc. (GNI Group)
Responsible party
Sponsor
First posted
Nov 20, 2014
Start date
Jan 2015
Primary completion
Jun 2016 (estimated)
Last update
Nov 20, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion